Skip to main content
Clinical Trials/ISRCTN10903557
ISRCTN10903557
Active, not recruiting
未知

Evaluation of the clinical benefits resulting from the application of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel in diagnostics and treatment of bloodstream infections among hospitalized patients

bioMérieux SSC Europe Sp. z o. o.0 sites150 target enrollmentJanuary 11, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
bioMérieux SSC Europe Sp. z o. o.
Enrollment
150
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 11, 2023
End Date
December 31, 2023
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
bioMérieux SSC Europe Sp. z o. o.

Eligibility Criteria

Inclusion Criteria

  • 1\. Positive blood culture will be eligible for the study
  • 2\. Two sets of blood (2x aerobic, 2x anaerobic)
  • 3\. Age \>18 years
  • 4\. Informed consent form to participate in the study

Exclusion Criteria

  • 1\. Age under 18 years
  • 2\. Refusal to participate in the study
  • 3\. Positive blood culture for the 72 hours follow\-up (ex. for Staphylococcus aureus bacteriemia).
  • 4\. Patients with blood PCR tests ordered outside the established research protocol and the established randomization. (PCR test ordered by the attending physician due to the patient's severe condition). \* in our hospital, the doctor can order a PCR test from blood on his own in the case of a patient in a life\-threatening condition, in shock, or for other reasons. Such patients will not be eligible for our study. They may constitute an interesting group of patients in the future, which can be compared with group A planned by our team, where, in addition to the blood PCR test, consultations will be provided on the correct treatment with the appropriate selection of ATB as well as the dosage and duration of treatment.

Outcomes

Primary Outcomes

Not specified

Similar Trials